Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria
Authors:
- 19 September 2011
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 44 (3) , 182-189
Abstract
Objective: To analyze the indications for and the efficacy of parenteral fosfomycin, especially against multidrug-resistant (MDR) and pan-resistant bacterial infections.Patients and methods: During a unique crisis in fosfomycin production, the supply of this antibiotic had to be carefully monitored in France over a 10-week period. One hundred and sixteen assessable patients were included in a prospective cohort study.Results: The main indications for use were osteoarthritis, lung infection, urinary tract infection, and bacteraemia. The 2 bacteria most frequently involved were Pseudomonas aeruginosa and methicillin-resistant Staphylococcus. MDR bacteria were seen in 71.5% (83/116) of cases, especially MDR P. aeruginosa (n = 28). Critical situations were common, with 44.0% (51/116) of hospitalizations occurring in an intensive care unit and 22.4% (26/116) of patients with septic shock. The overall outcome was favourable in 76.8% of cases (76/99 assessable patients).Conclusion: This study provided a unique opportunity to describe the use of fosfomycin and assess its efficacy, especially against MDR bacterial infections, even in critical situations.Keywords
This publication has 26 references indexed in Scilit:
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-ChallengeNew England Journal of Medicine, 2009
- Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal InfectionsClinical Infectious Diseases, 2008
- Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram‐Negative Bacilli: Need for International Harmonization in TerminologyClinical Infectious Diseases, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Polymyxins: old antibiotics are backThe Lancet, 2006
- Nosocomial Infections Due to Multidrug‐Resistant Pseudomonas aeruginosa: Epidemiology and Treatment OptionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Evaluation of the NCCLS Extended-Spectrum β-Lactamase Confirmation Methods forEscherichia coliwith Isolates Collected during Project ICAREJournal of Clinical Microbiology, 2003
- Development of Antimicrobial Agents in the Era of New and Reemerging Infectious Diseases and Increasing Antibiotic ResistanceJAMA, 2001
- Fosfomycin trometamolJournal of Antimicrobial Chemotherapy, 1994
- Phosphonomycin, a New Antibiotic Produced by Strains of StreptomycesScience, 1969